We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging McKesson (MCK) This Year?
Read MoreHide Full Article
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has McKesson (MCK - Free Report) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
McKesson is a member of our Medical group, which includes 983 different companies and currently sits at #8 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. McKesson is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for MCK's full-year earnings has moved 1.8% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the latest available data, MCK has gained about 23.9% so far this year. Meanwhile, stocks in the Medical group have lost about 3.5% on average. As we can see, McKesson is performing better than its sector in the calendar year.
Another Medical stock, which has outperformed the sector so far this year, is Cencora (COR - Free Report) . The stock has returned 27.4% year-to-date.
Over the past three months, Cencora's consensus EPS estimate for the current year has increased 2.5%. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, McKesson belongs to the Medical - Dental Supplies industry, a group that includes 14 individual companies and currently sits at #30 in the Zacks Industry Rank. This group has gained an average of 0.8% so far this year, so MCK is performing better in this area.
In contrast, Cencora falls under the Medical Services industry. Currently, this industry has 58 stocks and is ranked #89. Since the beginning of the year, the industry has moved -6.3%.
Investors with an interest in Medical stocks should continue to track McKesson and Cencora. These stocks will be looking to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Are Medical Stocks Lagging McKesson (MCK) This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has McKesson (MCK - Free Report) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
McKesson is a member of our Medical group, which includes 983 different companies and currently sits at #8 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. McKesson is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for MCK's full-year earnings has moved 1.8% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the latest available data, MCK has gained about 23.9% so far this year. Meanwhile, stocks in the Medical group have lost about 3.5% on average. As we can see, McKesson is performing better than its sector in the calendar year.
Another Medical stock, which has outperformed the sector so far this year, is Cencora (COR - Free Report) . The stock has returned 27.4% year-to-date.
Over the past three months, Cencora's consensus EPS estimate for the current year has increased 2.5%. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, McKesson belongs to the Medical - Dental Supplies industry, a group that includes 14 individual companies and currently sits at #30 in the Zacks Industry Rank. This group has gained an average of 0.8% so far this year, so MCK is performing better in this area.
In contrast, Cencora falls under the Medical Services industry. Currently, this industry has 58 stocks and is ranked #89. Since the beginning of the year, the industry has moved -6.3%.
Investors with an interest in Medical stocks should continue to track McKesson and Cencora. These stocks will be looking to continue their solid performance.